A Drill Can Help Identify Right Time To Sell Leaders
at Investor's Business Daily - 15 mins ago
When leading stocks fall, you need to read the situation impartially. However, if you have a position in a top stock from a top group, emotions can cloud judgment. You might sell in fear, or you might hold firm in stubbornness. A drill is the best...
Stocks Rise In Higher Volume; Gilead Up After Hours
at Investor's Business Daily - 1 hr 11 mins ago
Stocks rose in higher volume Tuesday, with the Nasdaq and S&P 500 notching their sixth straight gains amid a flurry of buyout activity in the drugs industry. The Nasdaq rose 1%, while the S&P 500 and the Dow Jones industrial average each rose 0.4%....
Sarepta Soars on Eteplirsen Submission Plans - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 1 hr 41 mins ago
Sarepta shares soared over 39% after the company announced it would submit a NDA for eteplirsen by year end.
Biotech Earnings Preview
Brian Orelli, The Motley Fool - Motley Fool - Tue Apr 22, 1:00PM CDT
It's Fools' favorite time of the year: earnings season. In the video below, senior biotech specialist Brian Orelli and health-care bureau chief Max Macaluso discuss a few biotechs that will release first quarter earnings shortly. Gilead Sciences...
Keep an Eye on these 3 Biotech Stocks - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Tue Apr 22, 10:49AM CDT
This sell-off was more due to a change in sentiment rather than a shift in industry fundamentals.
Alexion Likely to Keep Earnings Streak Alive - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 22, 10:00AM CDT
Alexion is set to report first quarter 2014 results before the opening bell on Apr 24.
Insider Trading Alert - BIIB, JAZZ And KWK Traded By Insiders
at The Street - Tue Apr 22, 9:15AM CDT
Stocks with insider trader activity include BIIB, JAZZ and KWK
Cytokinetics, Incorporated (CYTK) Jumps: Stock Up 13.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 22, 8:39AM CDT
Cytokinetics, Incorporated was a big mover last session, as its shares rose nearly 14% on the day.
Zacks Rank #1 Additions for Tuesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 22, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
Sarepta Therapeutics (SRPT) Soars: Stock Up 39.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 22, 7:51AM CDT
Sarepta Therapeutics, Inc. was a big mover last session, as its shares rose over 39% on the day.
ANI Pharmaceuticals, Inc. (ANIP) Looks Strong: Stock Soars 20.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 22, 7:44AM CDT
ANI Pharmaceuticals, Inc. was a big mover last session, as the company saw its shares surge nearly 21% on the day.
Should You Get Rid of Retrophin (RTRX) Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 22, 7:41AM CDT
Retrophin (RTRX) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter as well as the current year.
Biogen Idec enters into license agreement with Amunix for XTENylated Factor VIII
M2 - Tue Apr 22, 6:49AM CDT
US based biotechnology company Amunix Operating disclosed on Monday that Biogen Idec (NASDAQ:BIIB) has exercised its option to sign an exclusive, worldwide license agreement to research and develop novel, fully-recombinant Factor VIII products with improved therapeutic properties.
What to Watch for in Biotech Earnings This Week
George Budwell, The Motley Fool - Motley Fool - Mon Apr 21, 5:30PM CDT
Biotech stocks started the year off on a tear but have moved lower lately in dramatic fashion. For instance, the iShares Nasdaq Biotech Index is now down over 2% for the year, after gaining double digits at one point in early February. Pundits and...
Will Amgen (AMGN) Miss This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 21, 5:20PM CDT
Amgen has an Earnings ESP of 0.00% with a Zacks Rank #1 (Strong Buy).
Look for Shares of Biogen Idec to Potentially Pullback after Yesterday's 2.56% Rise
Comtex SmarTrend(R) - Mon Apr 21, 4:12PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $290.20 to a high of $298.57. Yesterday, the shares gained 2.6%, which took the trading range above the 3-day high of $296.00 on volume of 981,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
After Yesterday's Rally of 2.56% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Apr 21, 4:11PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $290.20 to a high of $298.57. Yesterday, the shares gained 2.6%, which took the trading range above the 3-day high of $296.00 on volume of 981,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Will Gilead (GILD) Beat Q1 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 21, 9:50AM CDT
Gilead is set to report first quarter 2014 results on Apr 22 after the market closes
Biogen Idec Signs License Agreement With Amunix for XTENylated Factor VIII
Marketwire - Mon Apr 21, 7:02AM CDT
Amunix Operating Inc. announced today that Biogen Idec (NASDAQ: BIIB) has exercised its option to enter into an exclusive, worldwide license agreement to research and develop novel, fully-recombinant Factor VIII products with improved therapeutic properties. Under the terms of the option agreement, Amunix will receive an upfront $1 million payment and will also be eligible to receive up to $38 million in clinical and commercial milestone payments. In addition, royalties will be paid on commercial sales by Biogen Idec for Factor VIII products incorporating Amunix proprietary XTEN technology.
Meet the Company That's Changing the Multiple Sclerosis Treatment Landscape
Sean Williams, The Motley Fool - Motley Fool - Sat Apr 19, 1:05PM CDT
Here at The Motley Fool we spend a lot of time dissecting companies at the leading edge of the largest investment opportunities. Being a specialist in the Health Care sector, that means I devote a lot of my research to drugs aimed at treating some of...